FDA issued warning letters after concerns surrounding pharmaceutical supply chains: April news roundup

One in five drug GMP warning letters that the FDA issued involved concerns surrounding supply chains

A recent study found that in 2022, one in five drug GMP warning letters that the FDA issued involved concerns surrounding supply chains.

The distribution of pharmaceutical ingredients became a priority, particularly with supply chains that were distributing opioid and alcohol-based hand sanitisers. Some of the letters issued in 2022 by the FDA were to excipient firms, with one being a glycerin supplier in Mexico, and another being a unit of DuPont.

To read the full breakdown of what worried the FDA the most about pharmaceutical supply chains, check out the full article now.

Bringing the pharmaceutical supply chain into the future

The past few years have laid bare the work that needed to be done across the entire pharmaceutical supply chain industry to ensure the continuation of operations in the event of global threats, such as the pandemic. The future must be one that moves us away from being reactive and towards being an industry that is proactive. A recent article by Inside Big Data details the role that advanced data analytics should play in this transformation, which is already underway.

They argue that ‘data, and more specifically, the combination of simulation (predictive) and operational (real-time) data, has the potential to make a seismic difference in building a reliable and effective pharmaceutical supply chain.’

To learn more, click here.

Industry leaders Controlant establish themselves in Denmark

For years now, Controlant (who we recently partnered with to produce our 2023 LogiPharma benchmarking report) has been helping leading pharmaceutical and logistics companies to achieve more reliable and cost-effective supply chain operations. Now, as they plan for the growth that is to come, they have opened a new office in Denmark.

But who are Controlant? According to their website, Controlant 'is a global leader in the digital transformation of pharma supply chains.’ Their vision is to ‘deliver a zero-waste supply chain’ for their partners and the planet through ‘digitalization, automation, and transformation of the pharma supply chain.’

The company employs over 430 people across 40 countries, with the latest office in Copenhagen being its newest subsidiary. Gísli Herjólfsson, the CEO and co-founder of Controlant had this to say:

“Controlant is growing fast, and we have ambitious goals to make pharma supply chains around the world agile, resilient, and sustainable so that medicines and vaccines reach the people who need them, with zero waste.  To ensure we are fully prepared for the journey ahead, we are expanding globally, and have established an office in Copenhagen - a strategic location with close proximity to some of the world's leading pharmaceutical companies and logistics providers. Close collaboration with our industry partners will play a critical role in digitizing, automating, and ultimately, transforming global pharma supply chains.” 

To learn more about Controlant, download your free copy of the 2023 LogiPharma benchmarking report.